Do analysts rate GRCE or KPRX?

Grace Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 185.71%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Grace Therapeutics is more favorable than Kiora Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRCE or KPRX more profitable?

Grace Therapeutics' return on equity of -36.11% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -36.11% -34.39% Kiora Pharmaceuticals N/A -63.38% -44.33%

Do analysts rate FLNA or KPRX?

Cassava Sciences currently has a consensus price target of $5.00, suggesting a potential upside of 509.68%. Given Cassava Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Cassava Sciences is more favorable than Kiora Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FLNA or KPRX more profitable?

Cassava Sciences' return on equity of -58.78% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -58.78% -36.74% Kiora Pharmaceuticals N/A -63.38% -44.33%

Do analysts rate KPRX or ATHE?

Alterity Therapeutics has a consensus price target of $10.00, indicating a potential upside of 120.26%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Alterity Therapeutics is more favorable than Kiora Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher valuation & earnings, KPRX or ATHE?

Kiora Pharmaceuticals has higher revenue and earnings than Alterity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kiora Pharmaceuticals $16.02M 0.70 -$10.84M -$2.51 N/A Alterity Therapeutics N/A N/A -$15.88M N/A N/A

Is KPRX or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Kiora Pharmaceuticals N/A -63.38% -44.33% Alterity Therapeutics N/A N/A N/A

Do analysts prefer CRVO or KPRX?

CervoMed presently has a consensus price target of $21.00, suggesting a potential upside of 720.31%. Given CervoMed's stronger consensus rating and higher possible upside, equities research analysts clearly believe CervoMed is more favorable than Kiora Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CervoMed 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Kiora Pharmaceuticals (KPRX) Competitors

$2.55 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

KPRX vs. GRCE, KPTI, FLNA, ATHE, and CRVO

Should you buy Kiora Pharmaceuticals stock or one of its competitors? Kiora Pharmaceuticals's main competitors and comparable companies include Grace Therapeutics (GRCE), Karyopharm Therapeutics (KPTI), Cassava Sciences (FLNA), Alterity Therapeutics (ATHE), and CervoMed (CRVO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Kiora Pharmaceuticals compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 10.8% of Grace Therapeutics shares are held by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Grace Therapeutics has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.34, suggesting that its stock price is 134% less volatile than the broader market.

Grace Therapeutics' return on equity of -36.11% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-36.11%	-34.39%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

In the previous week, Grace Therapeutics had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 1 mentions for Grace Therapeutics and 0 mentions for Kiora Pharmaceuticals. Grace Therapeutics' average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Grace Therapeutics	Neutral
Kiora Pharmaceuticals	Neutral

Grace Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 185.71%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Grace Therapeutics is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Grace Therapeutics has higher earnings, but lower revenue than Kiora Pharmaceuticals. Grace Therapeutics is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A
Kiora Pharmaceuticals	$16.02M	0.70	-$10.84M	-$2.51	N/A

Summary

Grace Therapeutics beats Kiora Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Kiora Pharmaceuticals has lower revenue, but higher earnings than Karyopharm Therapeutics. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.28	-$196.04M	-$13.09	N/A
Kiora Pharmaceuticals	$16.02M	0.70	-$10.84M	-$2.51	N/A

Kiora Pharmaceuticals has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-153.28%	N/A	-145.18%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

Karyopharm Therapeutics presently has a consensus target price of $11.50, suggesting a potential upside of 542.46%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Karyopharm Therapeutics is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Karyopharm Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.34, indicating that its share price is 134% less volatile than the broader market.

In the previous week, Karyopharm Therapeutics had 5 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 5 mentions for Karyopharm Therapeutics and 0 mentions for Kiora Pharmaceuticals. Karyopharm Therapeutics' average media sentiment score of 0.12 beat Kiora Pharmaceuticals' score of 0.00 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Karyopharm Therapeutics	Neutral
Kiora Pharmaceuticals	Neutral

Summary

Karyopharm Therapeutics beats Kiora Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Cassava Sciences' return on equity of -58.78% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cassava Sciences has a beta of -0.69, indicating that its stock price is 169% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.34, indicating that its stock price is 134% less volatile than the broader market.

In the previous week, Cassava Sciences' average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Cassava Sciences	Neutral
Kiora Pharmaceuticals	Neutral

Cassava Sciences currently has a consensus price target of $5.00, suggesting a potential upside of 509.68%. Given Cassava Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Cassava Sciences is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Kiora Pharmaceuticals has higher revenue and earnings than Cassava Sciences. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Kiora Pharmaceuticals	$16.02M	0.70	-$10.84M	-$2.51	N/A

Summary

Cassava Sciences beats Kiora Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Alterity Therapeutics?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Kiora Pharmaceuticals has higher revenue and earnings than Alterity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.70	-$10.84M	-$2.51	N/A
Alterity Therapeutics	N/A	N/A	-$15.88M	N/A	N/A

Alterity Therapeutics' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%
Alterity Therapeutics	N/A	N/A	N/A

Kiora Pharmaceuticals has a beta of -0.34, suggesting that its share price is 134% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

In the previous week, Alterity Therapeutics had 2 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 2 mentions for Alterity Therapeutics and 0 mentions for Kiora Pharmaceuticals. Alterity Therapeutics' average media sentiment score of 0.13 beat Kiora Pharmaceuticals' score of 0.00 indicating that Alterity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Kiora Pharmaceuticals	Neutral
Alterity Therapeutics	Neutral

Alterity Therapeutics has a consensus price target of $10.00, indicating a potential upside of 120.26%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Alterity Therapeutics is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 0.5% of Kiora Pharmaceuticals shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Alterity Therapeutics beats Kiora Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to CervoMed?

CervoMed (NASDAQ:CRVO) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Kiora Pharmaceuticals has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Kiora Pharmaceuticals' return on equity of -63.38% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-156.02%	-128.34%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

In the previous week, CervoMed's average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
CervoMed	Neutral
Kiora Pharmaceuticals	Neutral

Kiora Pharmaceuticals has higher revenue and earnings than CervoMed. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	9.65	-$26.97M	-$3.22	N/A
Kiora Pharmaceuticals	$16.02M	0.70	-$10.84M	-$2.51	N/A

CervoMed presently has a consensus price target of $21.00, suggesting a potential upside of 720.31%. Given CervoMed's stronger consensus rating and higher possible upside, equities research analysts clearly believe CervoMed is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

25.2% of CervoMed shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 35.8% of CervoMed shares are held by company insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CervoMed has a beta of -0.64, indicating that its stock price is 164% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.34, indicating that its stock price is 134% less volatile than the broader market.

Summary

Kiora Pharmaceuticals beats CervoMed on 8 of the 15 factors compared between the two stocks.

Get Kiora Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KPRX vs. The Competition

Export

Metric	Kiora Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.27M	$12.19B	$7.21B	$12.89B
Dividend Yield	N/A	2.59%	2.54%	9.13%
P/E Ratio	-1.02	792.20	273.84	25.45
Price / Sales	0.70	760.84	625.55	100.83
Price / Cash	N/A	15.18	28.92	35.62
Price / Book	0.58	11.09	11.01	6.39
Net Income	-$10.84M	$2.83B	$3.49B	$358.69M
7 Day Performance	1.59%	4.42%	1.63%	0.22%
1 Month Performance	-3.41%	6.88%	4.42%	-0.10%
1 Year Performance	-4.85%	10.00%	24.21%	14.04%

Kiora Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
KPRX Kiora Pharmaceuticals	0.7631 of 5 stars	$2.55 flat	N/A	-4.9%	$11.28M	$16.02M	N/A	10
GRCE Grace Therapeutics	1.4435 of 5 stars	$2.14 +1.9%	$6.00 +180.4%	-34.4%	$44.17M	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	2.6695 of 5 stars	$1.79 -3.2%	$11.50 +542.5%	-72.9%	$41.96M	$146.07M	N/A	380
FLNA Cassava Sciences	1.4697 of 5 stars	$0.86 +0.0%	$5.00 +483.0%	-62.0%	$41.41M	N/A	N/A	20
ATHE Alterity Therapeutics	2.6379 of 5 stars	$4.52 -0.7%	$10.00 +121.2%	N/A	$40.35M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KPRX) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiora Pharmaceuticals (KPRX) Competitors

KPRX vs. GRCE, KPTI, FLNA, ATHE, and CRVO

How does Kiora Pharmaceuticals compare to Grace Therapeutics?

Summary

How does Kiora Pharmaceuticals compare to Karyopharm Therapeutics?

Summary

How does Kiora Pharmaceuticals compare to Cassava Sciences?

Summary

How does Kiora Pharmaceuticals compare to Alterity Therapeutics?

Summary

How does Kiora Pharmaceuticals compare to CervoMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX vs. The Competition

Kiora Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiora Pharmaceuticals (KPRX) Competitors

KPRX vs. GRCE, KPTI, FLNA, ATHE, and CRVO

How does Kiora Pharmaceuticals compare to Grace Therapeutics?

Do insiders and institutionals have more ownership in GRCE or KPRX?

Which has more risk & volatility, GRCE or KPRX?

Is GRCE or KPRX more profitable?

Does the media refer more to GRCE or KPRX?

Do analysts rate GRCE or KPRX?

Which has higher earnings & valuation, GRCE or KPRX?

Summary

How does Kiora Pharmaceuticals compare to Karyopharm Therapeutics?

Do insiders & institutionals believe in KPTI or KPRX?

Which has better valuation & earnings, KPTI or KPRX?

Is KPTI or KPRX more profitable?

Do analysts recommend KPTI or KPRX?

Which has more volatility & risk, KPTI or KPRX?

Does the media refer more to KPTI or KPRX?

Summary

How does Kiora Pharmaceuticals compare to Cassava Sciences?

Is FLNA or KPRX more profitable?

Do insiders and institutionals hold more shares of FLNA or KPRX?

Which has more risk & volatility, FLNA or KPRX?

Does the media favor FLNA or KPRX?

Do analysts rate FLNA or KPRX?

Which has higher valuation & earnings, FLNA or KPRX?

Summary

How does Kiora Pharmaceuticals compare to Alterity Therapeutics?

Which has higher valuation & earnings, KPRX or ATHE?

Is KPRX or ATHE more profitable?

Which has more volatility and risk, KPRX or ATHE?

Does the media prefer KPRX or ATHE?

Do analysts rate KPRX or ATHE?

Do institutionals & insiders have more ownership in KPRX or ATHE?

Summary

How does Kiora Pharmaceuticals compare to CervoMed?

Is CRVO or KPRX more profitable?

Does the media favor CRVO or KPRX?

Which has better valuation & earnings, CRVO or KPRX?

Do analysts prefer CRVO or KPRX?

Do insiders and institutionals hold more shares of CRVO or KPRX?

Which has more volatility and risk, CRVO or KPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX vs. The Competition

Kiora Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools